Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab for chronic venous ulcers
ACTRN12620000235909Phase 2Terminated
- Sponsor
- Frazer Institute
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in stasis ulcer comparing Ixekizumab + standard wound care with Placebo + standard wound care (2 arms). Primary endpoints: Proportion achieving at least 40% wound size reduction and Change in wound inflammatory biomarkers. Started Sep 2020; status: terminated.
02
Drugs
ixekizumab
03
Conditions
stasis ulcer
Beyond the preview
Go deeper on ACTRN12620000235909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000235909.